Cohort (LON:CHRT)

Benzinga  8 hrs ago  Comment 
Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) an oncology company focused on the development of innovative approaches to targeting and treating prostate cancer, announced today the completion of enrollment in the chemotherapy naïve cohort in its...
Benzinga  Apr 23  Comment 
Galectin Therapeutics (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that all eight (8) patients have received their first infusion in cohort 2 of its Phase 1...
Benzinga  Apr 17  Comment 
Galectin Therapeutics (Nasdaq: GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, announced today that the first patient in cohort 2 of its Phase 1 clinical trial of GR-MD-02 in patients with...
Forbes  Apr 15  Comment 
Baby Boomers. Gen X. Millennials. These cohort names get thrown around a lot. That’s because generational marketing is big business. And it makes for simpler discussions to have large groups of people grouped together in big chunks. It’s...
MedPage Today  Apr 11  Comment 
(MedPage Today) -- Indicators of periodontal disease were common in a large cohort of patients with established coronary heart disease and were associated with elevated cardiovascular risk, although causal links remain elusive, researchers found.
Clusterstock  Apr 6  Comment 
The above table comes from Bill McBride at Calculated risk, and it shows the changes to the populations of various age groups over the last six years. There's been a lot of talk about the declining Labor Force Participation Rate, and how much...
Benzinga  Apr 1  Comment 
In a report published Tuesday, MLV & Co analyst Vernon T. Bernardino reiterated a Buy rating and $20.00 price target on Galectin Therapeutics (NASDAQ: GALT). In the report, MLV & Co noted, “Albeit from 8 patients, an abundance of data support...  Apr 1  Comment 
Visit at for the full story.
MedPage Today  Mar 31  Comment 
WASHINGTON (MedPage Today) -- Years after results from the original trial lowered the bar on eligibility for ICDs, the latest data from the MADIT-CRT cohort are likely to introduce yet another group of patients to device therapy, but this time in...
MedPage Today  Mar 29  Comment 
WASHINGTON (MedPage Today) -- Transcatheter aortic valve implantation (TAVI) with the CoreValve device improved survival compared with surgery in the high-risk pivotal trial cohort.



Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki